Press "Enter" to skip to content

USFDA inspection at Indore facility ends with zero observations: Cipla

"We would like to inform you that the USFDA (US Food and Drug Administration) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019," the company said in a BSE filing.

Original source: https://health.economictimes.indiatimes.com/news/pharma/usfda-inspection-at-indore-facility-ends-with-zero-observations-cipla/69381992?utm_source=RSS&utm_medium=ETRSS

Also Read:   PharmEasy in talks with SoftBank to raise $100M: report